Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate

Foresta C, Guarneri G, Scanelli G, Scandellari C (1984) Osteoporosis in elderly men (letter). Clin Endocrinol 21(3):309–310Google Scholar

Foresta C, Ruzza G, Mioni R, Guarneri G, Gribaldo R, Meneghello A, Mastrogiacomo I (1984) Osteoporosis in decline of gonadal function in the elderly male. Horm Res 19(1):18–22Google Scholar

Guarneri G, Foresta C, Ruzza G, Meneghello A, Sidran MP, Cafiero F (1981) Studio ormonale dell'osteoporosi senile nell'uomo. Minerva Med 72:2167–2171Google Scholar

Foresta C, Busnardo B, Ruzza G, Zanatta G, Mioni R (1983) Lower calcitonin levels in young hypogonadic men with osteoporosis. Horn Metab Res 15(4):206–207Google Scholar

Baran DT, Bergfeld MA, Teitelbaum SL, Avioli LV (1978) Effect of testosterone therapy on bone formation in an osteoporotic hypogonadal male. Calcif Tissue Res 26(2):103–106Google Scholar

Foresta C, Scanelli G, Zanatta G, Busnardo B, Scandellari C (1987) Reduced calcitonin reserve in young hypogonadic osteoporotic men. Horm Metab Res 19(6):275–277Google Scholar

Francis RM, Peacock M, Aaron JE, Selby PL, Taylor GA, Thompson J, Marshall DH, Horsman A (1986) Osteoporosis in hypogonadal men: role of decreased plasma 1,25 dihydroxyvitamin D, calcium malabsorption and low bone formation. Bone 7(4):261–268Google Scholar

Greenspan SL, Neer RM, Ridgeway EC, Klibanski A (1986) Osteoporosis in men with hyperprolactinaemic hypogonadism. An Intern Med 104(6):777–782Google Scholar

Foresta C, Zanatta G, Busnardo B, Scanelli G, Scandellari C (1985) Testosterone and calcitonin levels in hypogonadal osteoporotic young men. J Endocrinol Invest 8(4):377–379Google Scholar

Seeman E, Melton LJ, O'Fallon WM, Riggs BL (1983) Risk factors for spinal osteoporosis in men. Am J Med 75:977–983Google Scholar

Delmas P, Meunier PJ (1981) O'osteoporose au cours du syndrome de Klinefelter donnes histologiques osseuses quantitatives dans cinq cas. Relation avec la carence hormonale. Nouv Presse Med 10:687–690Google Scholar

Foresta C, Meneghello A, Ruzza G, Zaldera P, Mioni R (1981) Osteoporosis in hypogonadal young men. J Endocrinol Invest 4 (suppl 2):54Google Scholar

Odell WD, Swerdloff RS (1976) Male hypogonadism. West J Med 124:446–475Google Scholar

Saville PD (1973) The syndrome of spinal osteoporosis. Clin Endocrinol Metab 2:177–185Google Scholar

Francis RM, Peacock M, Nordin BEC, Horsman A, Aaron JE (1983) Osteoporosis in the male. J Bone Joint Surg 65B:90Google Scholar

Velentzas L, Karras D (1981) L'osteoporose et L'hypogonadisme. Nouv Presse Med 10:2520Google Scholar

Smith DAS, Walker MS (1977) Changes in plasma steroids and bone density in Klinefelter's syndrome. Calcif Tissue Res 22 (suppl):225–228Google Scholar

Goulding A, Gold E (1989) A new way to induce oestrogen-deficiency osteopenia in the rat: comparison of the effects of surgical ovarietomy and the administration of the LHRH agonist on bone resorption and composition. J Endocrinol 121:293–298Google Scholar

Lindsay R (1988) Sex steroids in the pathogenesis and prevention of osteoporosis. In: Osteoporosis aetiology, diagnosis and management. Riggs BL, Melton LJ III (eds) Raven Press, New York, pp 333–358Google Scholar

Stepan JJ, Lachman M, Zverina J, Pacavky V, Paylink DJ (1989) Castrated men exhibit bone loss—effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 69:523–527Google Scholar

Axelrod DW, Lachman LB, Judge D (1989) Resorptive hypercalciuria and increased interleukin I in a young man with hypogonadism and osteoporosis—reversal with androgen treatment. Clin Res 37:355AGoogle Scholar

Gallagher JC, Lawrence B, De Luca HF (1980) Effect of oestrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J Clin Endocrinol Metab 51:1359–1364Google Scholar

Shamonki IM, Fruman AM, Tetaryn IV, Meldrum DR, Davidson BH, Parthermore JG, Judd HL, Deftos LJ (1987) Agerelated changes of calcitonin secretion in women. J Clin Endocrinol Metab 50:437Google Scholar

Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ (1989) Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 124(3):1576–1578Google Scholar

Tyrrell CJ (1992) Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer. Prostate (suppl) 4:97–104Google Scholar

Mahler C, Van Cangh P, Bouffioux C, Keuppens F, Coeck C, Ongena P, Denis L (1990) Endocrine effects of casodex, a new non-steroidal antiandrogen. In: Murphy G, Khoury S, Chatelain S, Denis L (eds) Recent advances in urological cancers: diagnosis and treatment 1990. pp 42–45 2nd Int Sym on Recent Advances in Urologic Cancer, Paris, 27–29Google Scholar

Verhelst J, Keuppens F, Vancangh P, Bouffioux C, Ongena P, Denis L, Mahler C (1991) Endocrine effects of casodex, a new antiandrogen. Eur J Cancer 27 (suppl 2): S118 Abs 694. ECCO6, 6th European Conference on Clinical Oncology and Cancer Nursing, Firenze, 27–31 Oct 1991.Google Scholar